CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed
Drug / intervention
Lopinavir/ritonavir +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00050895
NCT00050895Phase 3Completed
CompareCT.gov

A Phase III, Randomized, Open-Label Comparison of Lopinavir/Ritonavir Plus Efavirenz Versus Lopinavir/Ritonavir Plus 2 NRTIs Versus Efavirenz Plus 2 NRTIs as Initial Therapy for HIV-1 Infection

National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Jan 1, 2003·Updated Nov 1, 2021

In Brief

A Phase 3 clinical trial evaluating Lopinavir/ritonavir, Efavirenz, and 4 other interventions for HIV Infections. Completed, across 60 sites in 2 countries.

Detailed Summary

With new strategies and drugs available, many different regimens exist for the treatment of HIV. The purpose of this study is to compare three different anti-HIV drug regimens as first-time treatments for HIV infection.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesSouth Africa, United States
Collaborators--

Timeline

Phase 3CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 1, 2003
Study CompletionMar 1, 2006
TodayJul 2, 2026
Posted 23.5 years ago

Interventions

Lopinavir/ritonavirdrug

Efavirenzdrug

Stavudinedrug

Zidovudinedrug

Lamivudinedrug

Tenofovir disoproxil fumaratedrug